Abstract 1974
Background
The treatment efficacy of afatinib was assessed in patients with lung cancer harboring EGFRm which were detected from CtDNA. Primary objective was to prove overall response rate (ORR), and the secondary endpoints were progression free survival (PFS), overall survival and safety.
Methods
Ten mL of venous blood was withdrawn and plasma samples were stored at -20 °C until delivered to central laboratory. EGFRm analyses for CtDNA were performed by PANA Mutyper® EGFR kit (Panagene, Korea). EGFRm testing for tumor DNA were performed by in-house testing in each hospital with PNA clamp EGFR mutation kit or PANA Mutyper® EGFR kit.
Results
A total of 331 patients were screened for this trial from 2015 to 2018 March. Tumor genotyping showed 24.5% (81/331), while CtDNA showed 20.5% (68/331) of positivity to detect activating EGFRm (exon 19 deletions or exon 21 point mutations). Among 81 subjects with tumor DNA EGFRm positive subjects, 48 showed EGFRm in their CtDNA (59% sensitivity). Types of EGFRm were completely matched between tumor DNA and CtDNA in 48 subjects. Afatinib (40mg) was initiated in 21 (female:17, adenocarcinoma:20, NSCLC-NOS:1) subjects with mean age of 68.5 years (standard deviation 8.7). Dose modifications were made in 14 subjects (66.7%). Partial remission was observed in 13, stable disease in 5, progression in 1 and response was not evaluated in 2 subjects (ORR : 68.4% in response evaluable subjects). Eleven subjects showed EGFRm only in CtDNA (tumor DNA EGFR wild or unknown, Group 1), and 10 subjects revealed same EGFRm in their CtDNA and tumor DNA (Group 2).There was no significant difference (p = 0.35) in ORR between Group 1 (80.0%) and Group 2 (55.6%). As of April 2019, treatment is ongoing in 7 subjects, 1 withdrew consent, 2 discontinued treatment due to serious adverse events (SAEs). Seven SAEs including 2 drug induced lung disease were reported. Median PFS was 366 days, and there is no difference in PFS between Group1 vs. Group 2, and 40 mg vs. < 40 mg final dose groups.
Conclusions
Afatinib showed similar ORR and PFS in subjects with NSCLC harboring EGFRm in their CtDNA regardless of tumor EGFRm results.
Clinical trial identification
NCT02629523, December 14, 2015.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Boehringer Ingelheim and Panagene.
Disclosure
Y. Kim: Honoraria (self), Speaker Bureau / Expert testimony, Research grant / Funding (self): Boehringer Ingelheim; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): AstraZeneca; Honoraria (self), Speaker Bureau / Expert testimony, Research grant / Funding (self): Roche. I. Oh: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Funding (self): Roche. All other authors have declared no conflicts of interest.
Resources from the same session
5437 - Salivary cytokines and oral mucosa cells apoptosis in patients during hematopoietic cell transplantation: possible relationship with oral mucositis
Presenter: Luciana Corrêa
Session: Poster Display session 1
Resources:
Abstract
1483 - A randomized trial of sodium alginate prevention of radiation-induced esophagitis in patients with locally advanced NSCLC receiving concurrent chemoradiotherapy: OLCSG1401
Presenter: Toshihide Yokoyama
Session: Poster Display session 1
Resources:
Abstract
2047 - Taste and smell alterations (TSAs) in patients (pts) with stage II-III colon cancer (CC): a pilot within the PROTECT study
Presenter: Jeroen Derksen
Session: Poster Display session 1
Resources:
Abstract
5984 - Clinical characteristics are associated with acupuncture treatment response for xerostomia in cancer patients
Presenter: Wenli Liu
Session: Poster Display session 1
Resources:
Abstract
2845 - Psychosocial Distress of Adolescent and Young Adults with Cancer at Diagnosis: A Case-Matched Retrospective Cohort of 2045 Patients in British Columbia.
Presenter: Alannah Smrke
Session: Poster Display session 1
Resources:
Abstract
724 - Accuracy of distress thermometer to measure cancer-related mood disorders in Chinese patients with cancer
Presenter: Sudip Thapa
Session: Poster Display session 1
Resources:
Abstract
2357 - Modalities of biosimilar filgrastim use in clinical practice in >1000 patients receiving chemotherapy regimens with a rest period of ≤14 days: the TOPAZE study
Presenter: Jean Marc Phelip
Session: Poster Display session 1
Resources:
Abstract
1426 - The Effect of Increasing Doses of Pegfilgrastim (Peg) on Thrombocytopenia (T) in Breast Cancer (BC) Patients (pts) Receiving Taxotere (Doc), Doxorubicin, Cyclophosphamide (TAC) and Plinabulin (Plin)
Presenter: Douglas Blayney
Session: Poster Display session 1
Resources:
Abstract
712 - The use of intravenous ferric carboxymaltose without erythropoiesis-stimulating agents in the treatment of anemia in cancer patients undergoing chemotherapy with or without radiotherapy
Presenter: Hikmat Abdel-Razeq
Session: Poster Display session 1
Resources:
Abstract
1496 - Randomized, double-blind, cross-over Phase I study comparing pharmacokinetics, pharmacodynamics, safety and immunogenicity of a biosimilar pegfilgrastim with EU and US references
Presenter: Maria Velinova
Session: Poster Display session 1
Resources:
Abstract